

INVITATION



BELGIAN INVESTOR DAY

4 December 2013, Kongresshaus Zürich

AGENDA

From 8h15	Registration
8h30	Welcome by Vincent van Dessel, Chairman and CEO NYSE Euronext Brussels
9h00-12h00	Company meetings*
12h00-13h00	Lunch buffet: <i>"The Euro area, light at the end of the tunnel?"</i> by Damien Petit, Senior Economist Degroof
13h00-17h00	Company meetings *

*Each meeting takes max 50 minutes

VENUE

Kongresshaus Zürich

Gotthardstrasse 5, PF 2523
8022 Zürich



CONTACT

Laurent Goethals

Head Swiss Institutional Clients

Tel: +32 2 287 97 97

Fax: +32 2 233 91 85

E-mail: laurent.goethals@degroof.be



BELGIAN INVESTOR DAY

4 December 2013, Kongresshaus Zürich









COMPANY OVERVIEW

ABLYNX NV MCap € 366 m		<i>Edwin Moses, CEO</i> <i>Marieke Vermeersch, Head IR</i> Ablynx is a biopharmaceutical company specializes in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.
AGFA GEVAERT MCap € 294 m		<i>Kris Hoornaert, CFO</i> <i>Viviane Dictus, Director Corp. Comm. & IR</i> The Agfa-Gevaert Group develops, produces and distributes an extensive range of analog and digital imaging systems and IT solutions, mainly for the printing industry and the healthcare sector, as well as for specific industrial applications.
ARSEUS NV MCap € 675 m		<i>Ger van Jeveren, CEO</i> Arseus provides products, services and concepts for professionals and institutions active in the healthcare sector in Europe, North America, South America, Asia and Australia. Arseus is subdivided into four divisions and, among other things, is active in the markets for magistral preparations for pharmacies, dental products, medical and surgical products and medical IT solutions.
BARCO MCap € 760 m		<i>Carl Peeters, CFO</i> <i>Carl vanden Bussche, Director IR</i> Barco, a global technology company, designs and develops visualization products for a variety of selected professional markets. Barco is active in more than 90 countries with more than 3,900 employees worldwide.
BEFIMMO MCap € 1.125 B		<i>Benoît De Blicq, CEO</i> Befimmo is a Belgian REIT (Sicafil) specializing in investing in office buildings located mainly in the city centres notably in Brussels.
BEKAERT MCap € 1.63 B		<i>Jerome Lebecque, Head IR</i> Bekaert is a world market and technology leader in steel wire transformation and coatings.
DECEUNINCK MCap € 154 m		<i>Philippe Maeckelberghe, CFO</i> <i>Ludo Debever, IR</i> Deceuninck is a leading international designer and manufacturer of high quality PVC systems for windows and doors, cladding and roofline, interior and garden applications. The basic technology used by the company is extrusion of patented PVC and Twinson composite material.
ELIA MCap € 2.03 B		<i>Tom Schockaert, Head IR</i> Elia operates the Belgian high-voltage grid and is one of the four German transmission system operators, active in the north and east of Germany. With 1,900 employees and a transmission grid comprising some 18,300 km of high-voltage connections serving 30 million consumers, the Elia Group is one of Europe's top 5 TSOs.

BELGIAN INVESTOR DAY

4 December 2013, Kongresshaus Zürich

COMPANY OVERVIEW

EVS MCap € 653 m		<i>Geoffroy d'Oultremont, VP IR & Corp. Comm. Manager</i> EVS leads the market for live outside broadcast video production systems. Its products are intelligent recorders combined with highly reactive applications, such as the slow motion system.
GALAPAGOS NV MCap € 443 m		<i>Onno van de Stolpe, CEO</i> Galapagos is a clinical stage biotech company focused on developing novel medicines. The company specializes in osteoporosis, rheumatoid arthritis, osteoarthritis and Alzheimer's disease.
GIMV NV MCap € 914 m		<i>Kristof Vande Capelle, CFO</i> <i>Frank de Leenheer, Head IR</i> Gimv is a European investment company with over three decades of experience in private equity and venture capital. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 75 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employ over 26,000 professionals.
KBC ANCORA MCap € 1.8 B		<i>Franky Depickere, CEO</i> <i>Jan Bergmans, IR</i> KBC Ancora holds approximately 20% of the shares in KBC Group. The Company's principal activity is the maintenance and management of its shareholding in KBC Group.
KINEPOLIS MCap € 632 m		<i>Nicolas De Clercq, CFO</i> Kinopolis runs 23 multiplexes throughout Belgium, France, Spain, Switzerland and Poland. Besides cinema activities, Kinopolis is also active in film distribution, event organization, screen advertising and cinema property management.
MELEXIS NV MCap € 893 m		<i>Karien van Griensven, CFO</i> Melexis design and manufactures advanced integrated semiconductors, sensor IC's and programmable sensor IC systems that meet the requirements of the automotive industry.
RECTICEL MCap € 143 m		<i>Jean-Pierre Mellen, CFO</i> <i>Michel De Smedt, Head Comm. & IR</i> Recticel is a polyurethane foamer producing intermediate and end-products used in the automotive, bedding, construction and furniture industries.
TESSENDERLO CHEMIE MCap € 603 m		<i>Philip Ludwig, Head IR</i> Tessenderlo Group is a worldwide specialty company, focused on food, agriculture, water management and on valorizing bio-residuals. The group employs about 6,200 people and is a leader in most of its markets, with a consolidated revenue of 2.1 billion EUR in 2012.

BELGIAN INVESTOR DAY

4 December 2013, Kongresshaus Zürich

REGISTRATION FORM

Please return to the attention of:

Alexandra Krauss

E-mail: alexandra.krauss@degroof.be

INSTITUTION:
MRS-MS-MR:
FIRST NAME:
LAST NAME:
EMAIL:
DIRECT PHONE NUMBER:
MOBILE:

REQUESTED COMPANY MEETINGS

COMPANY NAME	DISCOVERY	FOLLOW-UP	PRIORITY LEVEL (1 TO 10)*

* (10 = highest priority)